Binimetinib

{
  "id": "MLC-T-ONC-001047",
  "term": "Binimetinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with encorafenib to treat melanoma that has spread or cannot be removed by surgery and has a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Binimetinib blocks proteins called MEK1 and MEK2, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called Mektovi.",
    "An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types."
  ],
  "synonyms": [
    "Mektovi"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/binimetinib/"
}